adenosine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
90 58-61-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • adenosine
  • adenine riboside
  • riboadenosine
  • beta-Adenosine
  • beta-D-Adenosine
  • adenoscan
A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter.
  • Molecular weight: 267.25
  • Formula: C10H13N5O4
  • CLOGP: -1.36
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 4
  • TPSA: 139.54
  • ALOGS: -1.28
  • ROTB: 2
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 5 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 7.48 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Oct. 30, 1989 FDA ASTELLAS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Supraventricular tachycardia 92.56 26.26 29 1871 13262 56276905
Ventricular tachycardia 59.04 26.26 22 1878 16879 56273288
Pneumonia aspiration 51.35 26.26 24 1876 32387 56257780
Atrial fibrillation 45.56 26.26 34 1866 108863 56181304
Underdose 38.88 26.26 18 1882 23739 56266428
Drug ineffective 37.83 26.26 90 1810 918899 55371268
Coma 37.62 26.26 24 1876 59631 56230536
Gastrooesophageal reflux disease 34.80 26.26 26 1874 83231 56206936
Exfoliative rash 32.58 26.26 9 1891 2652 56287515
Tachycardia 31.32 26.26 27 1873 105849 56184318
Ventricular fibrillation 30.17 26.26 12 1888 10940 56279227
Bronchospasm 29.20 26.26 13 1887 15656 56274511
Toxic epidermal necrolysis 27.88 26.26 14 1886 22028 56268139

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchospasm 96.90 22.90 31 1602 9941 31685770
Supraventricular tachycardia 87.79 22.90 29 1604 10278 31685433
Oesophageal ulcer haemorrhage 66.37 22.90 11 1622 178 31695533
Ventricular tachycardia 61.15 22.90 28 1605 23673 31672038
Drug ineffective 48.11 22.90 78 1555 395495 31300216
Mallory-Weiss syndrome 45.30 22.90 11 1622 1279 31694432
Arteriospasm coronary 45.30 22.90 13 1620 2878 31692833
Immune effector cell-associated neurotoxicity syndrome 33.76 22.90 10 1623 2469 31693242
Complex regional pain syndrome 32.07 22.90 7 1626 508 31695203
Myositis 31.41 22.90 14 1619 11080 31684631
Gingival bleeding 31.14 22.90 12 1621 6589 31689122
Rebound tachycardia 28.68 22.90 4 1629 18 31695693
Ventricular fibrillation 27.09 22.90 15 1618 18833 31676878
Atrioventricular block complete 24.85 22.90 11 1622 8554 31687157
Cardiac arrest 23.83 22.90 26 1607 89036 31606675

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Supraventricular tachycardia 159.36 23.01 52 3243 19658 70905491
Bronchospasm 117.60 23.01 43 3252 22749 70902400
Ventricular tachycardia 94.83 23.01 42 3253 36381 70888768
Arteriospasm coronary 70.02 23.01 21 3274 6003 70919146
Drug ineffective 64.69 23.01 137 3158 939615 69985534
Atrial fibrillation 58.06 23.01 56 3239 184292 70740857
Oesophageal ulcer haemorrhage 54.97 23.01 11 3284 580 70924569
Ventricular fibrillation 54.07 23.01 26 3269 27085 70898064
Mallory-Weiss syndrome 38.72 23.01 11 3284 2600 70922549
Exfoliative rash 35.12 23.01 11 3284 3626 70921523
Cardiac arrest 34.95 23.01 40 3255 159794 70765355
Tachycardia induced cardiomyopathy 34.76 23.01 6 3289 139 70925010
Immune effector cell-associated neurotoxicity syndrome 30.11 23.01 10 3285 3968 70921181
Underdose 29.83 23.01 18 3277 29365 70895784
Pneumonia aspiration 29.73 23.01 24 3271 62265 70862884
Cardiogenic shock 28.74 23.01 19 3276 36288 70888861
Atrioventricular block complete 28.58 23.01 14 3281 15149 70910000
Drug ineffective for unapproved indication 27.71 23.01 19 3276 38519 70886630
Myositis 26.69 23.01 14 3281 17475 70907674
Gingival bleeding 25.57 23.01 13 3282 15219 70909930
Complex regional pain syndrome 24.08 23.01 7 3288 1793 70923356

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C01EB10 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
OTHER CARDIAC PREPARATIONS
Other cardiac preparations
MeSH PA D000700 Analgesics
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D058913 Purinergic Agonists
MeSH PA D058906 Purinergic P1 Receptor Agonists
MeSH PA D018689 Sensory System Agents
MeSH PA D014665 Vasodilator Agents
FDA MoA N0000175788 Adenosine Receptor Agonists
FDA EPC N0000178375 Adenosine Receptor Agonist
CHEBI has role CHEBI:35620 vasodilator agents
CHEBI has role CHEBI:38070 antiarrhythmic agent
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:78675 fundamental metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Paroxysmal supraventricular tachycardia indication 67198005
Myocardial Perfusion Imaging Adjunct indication
Supraventricular tachycardia off-label use 6456007
Pericarditis contraindication 3238004 DOID:1787
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Disorder of autonomic nervous system contraindication 15241006
Complete atrioventricular block contraindication 27885002
Hypovolemia contraindication 28560003
Acute cerebrovascular insufficiency contraindication 29322000
Transplantation of heart contraindication 32413006
Sick sinus syndrome contraindication 36083008 DOID:13884
Low blood pressure contraindication 45007003
Aortic valve stenosis contraindication 60573004 DOID:1712
Left to right cardiovascular shunt contraindication 66130006
Mitral valve stenosis contraindication 79619009 DOID:1754
Pulmonary emphysema contraindication 87433001
Respiratory alkalosis contraindication 111378004
Second degree atrioventricular block contraindication 195042002
Asthma contraindication 195967001 DOID:2841
Left main coronary artery disease contraindication 371804009
Acute coronary syndrome contraindication 394659003
Respiratory insufficiency contraindication 409623005
Syncope due to Bradycardia contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.67 acidic
pKa2 12.33 acidic
pKa3 13.34 acidic
pKa4 3.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Adenosine receptor A2a GPCR AGONIST EC50 6.16 WOMBAT-PK CHEMBL
Adenosine receptor A1 GPCR AGONIST EC50 6.51 WOMBAT-PK CHEMBL
Adenosine receptor A2b GPCR AGONIST EC50 4.62 WOMBAT-PK CHEMBL
Adenosine receptor A3 GPCR AGONIST Ki 6.54 IUPHAR
Adenosine kinase Kinase IC50 6 WOMBAT-PK
Adenosine deaminase Enzyme Kd 4.60 WOMBAT-PK
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 5.36 CHEMBL
Adenosylhomocysteinase Enzyme Km 5.80 WOMBAT-PK
Phosphatidylinositol 4-kinase type 2-alpha Kinase INHIBITOR IC50 5 IUPHAR
Phosphatidylinositol 4-kinase type 2-beta Kinase INHIBITOR IC50 5 IUPHAR
Glyceraldehyde-3-phosphate dehydrogenase liver Enzyme IC50 4.46 CHEMBL
Histone-lysine N-methyltransferase, H3 lysine-79 specific Enzyme IC50 4 CHEMBL
Adenosine receptor A1 GPCR Ki 8.29 CHEMBL
Adenosine receptor A2a GPCR Ki 7.52 CHEMBL
Adenosine receptor A3 GPCR Ki 7 CHEMBL
Adenosine kinase Kinase Ki 5.05 CHEMBL
Adenosine A2 receptor GPCR Ki 8.30 CHEMBL
cAMP-dependent protein kinase A Kinase Ki 4.82 CHEMBL

External reference:

IDSource
4019507 VUID
N0000147627 NUI
D00045 KEGG_DRUG
215025 RXNORM
C0001443 UMLSCUI
CHEBI:16335 CHEBI
ADN PDB_CHEM_ID
CHEMBL477 ChEMBL_ID
DB00640 DRUGBANK_ID
D000241 MESH_DESCRIPTOR_UI
60961 PUBCHEM_CID
2844 IUPHAR_LIGAND_ID
K72T3FS567 UNII
003603 NDDF
004537 NDDF
004813 NDDF
108502004 SNOMEDCT_US
35431001 SNOMEDCT_US
4019507 VANDF
1072 MMSL
4135 MMSL
57772 MMSL
d00164 MMSL

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9809 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 20 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 0404-9809 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 20 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 0409-1932 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 25 sections
Adenocard HUMAN PRESCRIPTION DRUG LABEL 1 0469-8234 SOLUTION 3 mg INTRAVENOUS NDA 17 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6113 INJECTION 3 mg INTRAVENOUS ANDA 21 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 0703-8776 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 27 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 0703-8777 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 27 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 16714-180 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 27 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 16714-556 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 25 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 16714-972 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 27 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 16714-997 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 25 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 17478-542 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 21 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 17478-542 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 21 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 17478-542 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 21 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 17478-544 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 26 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 17478-544 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 26 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 17478-953 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 20 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 17478-953 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 20 sections
Adenosine HUMAN PRESCRIPTION DRUG LABEL 1 23155-258 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 25 sections
Too im Cell ALL IN ONE HUMAN OTC DRUG LABEL 3 24765-124 LOTION 0.40 mg TOPICAL OTC monograph not final 8 sections
adenosine HUMAN PRESCRIPTION DRUG LABEL 1 25021-301 INJECTION 3 mg INTRAVENOUS ANDA 23 sections
Tissen NF 10 HUMAN OTC DRUG LABEL 1 42491-1100 LIQUID 0.01 g TOPICAL unapproved drug other 8 sections
Tissen ICM 10 HUMAN OTC DRUG LABEL 1 42491-1200 LIQUID 0.01 g TOPICAL unapproved drug other 8 sections
Dr G deWrinkle BOOSTER ample by EGF HUMAN OTC DRUG LABEL 2 43948-3001 SOLUTION/ DROPS 0.04 mL TOPICAL OTC monograph final 4 sections
Dr G deWrinkle FORTIFIER by EGF HUMAN OTC DRUG LABEL 2 43948-3002 CREAM 0.01 mL TOPICAL OTC monograph final 4 sections
Dr G deWrinkle REFORMER by EGF HUMAN OTC DRUG LABEL 2 43948-3003 CREAM 0.02 mL TOPICAL OTC monograph final 4 sections
Super Plus Beblesh Balm Triple Functions SPF50 Plus PA 3Plus (40g) HUMAN OTC DRUG LABEL 6 49715-007 CREAM 0.02 g TOPICAL OTC monograph final 10 sections
The Prestige BB SPF25 PA 2Plus HUMAN OTC DRUG LABEL 4 49715-008 CREAM 0.02 g TOPICAL OTC monograph final 10 sections
The Oriental Gold BB SPF25 PA 2Plus HUMAN OTC DRUG LABEL 4 49715-010 CREAM 0.02 g TOPICAL OTC monograph final 10 sections
Absolute Total BB SPF37 PA 3Plus HUMAN OTC DRUG LABEL 4 49715-011 CREAM 0.02 g TOPICAL OTC monograph final 10 sections